MedTrace Logo

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2012-01-26

No results posted yet for this study

Summary

DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture kinetic (MiCK) assay will predict treatment outcome and can help to direct the chemotherapy of cancer subjects. This study is focused on subjects diagnosed with breast, ovarian, lung, and colon malignancies and low-grade lymphomas.

Study Objectives:

* To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients.
* To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients.

Conditions

  • Breast Neoplasms
  • Lung Neoplasms
  • Ovarian Neoplasms
  • Sarcoma, Soft Tissue

Interventions

OTHER

Laboratory Assay

Chemotherapy

OTHER

Mick Assay

Chemotherapy doctor determined from results

Sponsors & Collaborators

  • Pierian Biosciences

    lead INDUSTRY

Principal Investigators

  • Cary Presant, MD · Medical Director DiaTech Oncology

  • Pat Whitworth, MD · Director, Nashville Breast Center, PC

  • Alexander Zweibach, MD, PhD · Cancer Care Centers of South Texas

  • Karl Rogers, MD · Nashville Oncology Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243685 on ClinicalTrials.gov